**Existing Clinical Landscape:**
- **DDR Inhibitors in Cancer:** Extensive pipeline (PARP inhibitors: olaparib, talazoparib; ATR inhibitors: AZD6738)
- **Neurodegeneration DDR:** No current clinical programs targeting DDR in neurodegeneration
- **PPI Inhibitors:** Limited success (BCL-2 inhibitors, MDM2 inhibitors represent rare successes)
**Competitive Assessment:**
- **Blue Ocean:** No direct competition in neurodegeneration DDR space
- **Cancer Spillover Risk:** Cancer DDR programs could pivot to neurodegeneration
- **Technical Barriers:** PPI druggability remains challenging despite advances
**Safety Concerns:**
- **Essential Function Disruption:** RAD50-TBP interaction may be crucial for normal DNA repair
- **Cancer Risk:** Impaired DDR could increase malignancy risk in long-term treatment
- **Immune Dysfunction:** DDR proteins involved in immune surveillance
**Development Timeline & Cost:**
- **Target Validation:** 12-18 months ($3-8M) - Confirm PPI and functional relevance
- **Hit Identification:** 18-36 months ($10-25M) - HTS, fragment-based drug discovery
- **Lead Optimization:** 24-36 months ($15-40M) - ADME, selectivity optimization
- **IND-Enabling:** 18-24 months ($20-35M) - Extensive safety studies for novel target
- **Phase 1:** 18-24 months ($25-50M) - Extended safety evaluation
- **Total to Phase 1:** 7-10 years, $73-158M
**Key Risks:**
1. **Druggability:** RAD50-TBP interface may lack deep binding pockets
2. **Selectivity:** Distinguishing pathological vs. physiological interactions
3. **Regulatory:** Novel mechanism requires extensive non-clinical validation
## Overall Recommendation
**Most Viable Approach: Modified ASO Strategy**
- Focus on well-characterized dilncRNAs from specific damage contexts
- Partner with established ASO companies (Ionis, Antisense Therapeutics)
- Leverage existing CNS delivery infrastructure
- Estimated development cost: $90-175M to Phase 2
**Least Viable: MRN-PIC Inhibitors**
- High technical risk for PPI targeting
- Uncertain therapeutic window
- Extensive safety requirements for novel DDR target
- Estimated cost: $73-158M just to reach Phase 1
**Critical Next Steps:**
1. Sequence and characterize dilncRNAs from human neurodegeneration samples
2. Validate nuclear delivery of ASOs to damage foci
3. Establish disease-relevant biomarkers for target engagement
The ASO approach offers the best risk-adjusted return, leveraging established technology platforms while addressing a novel biological target.